查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541386

2024-2032 年按類型、治療方法、最終用戶和地區分類的血液惡性腫瘤市場報告

Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球血液惡性腫瘤市場規模達到603億美元。血癌盛行率不斷上升、擴大採用針對基因特徵的標靶療法和免疫療法，以及專注於血液癌症新療法的生物製藥管道的擴展是推動市場成長的一些關鍵因素。

血液惡性腫瘤市場分析：

主要市場促進因素：血液惡性腫瘤發生率上升，加上人口老化，正在推動對血液惡性腫瘤藥物的需求。此外，人們對早期診斷的認知不斷增強，以及診斷方式的改進，也促進了市場的成長。

主要市場趨勢：標靶治療、免疫療法和個人化醫療的創新正在改變血液癌症患者的治療選擇、改善結果並減少副作用，是促進血液惡性腫瘤市場收入的重要因素之一。

競爭格局：在全球市場營運的一些領先公司包括艾伯維公司、阿斯特捷利康公司、百時美施貴寶公司、禮來公司、羅氏公司、葛蘭素史克公司、強生公司、默克公司. Inc. 、諾華公司、輝瑞公司、賽諾菲公司和武田製藥有限公司等。

地理趨勢：血液惡性腫瘤市場在全球呈現強勁成長。在北美，這種成長可歸因於先進的醫療基礎設施和高發病率。歐洲緊隨其後，在研發方面進行了大量投資。在醫療保健支出增加和獲得先進治療的機會增加的推動下，亞太地區正在迅速崛起，從而促進了市場擴張。

挑戰與機會：血液惡性腫瘤市場面臨治療成本高、疾病生物學複雜、個人化治療需求等挑戰。然而，在推進標靶治療、免疫療法和診斷技術方面存在機會，以改善患者的治療結果並滿足對有效和個人化癌症護理解決方案不斷成長的需求。

血液惡性腫瘤市場趨勢：

血癌盛行率上升

血癌發病率不斷上升以及對新療法開發的日益重視主要推動了血液惡性腫瘤市場的成長。根據 Globocan 2020 的數據，亞洲的白血病發病率估計最高，2020 年診斷出 230,650 例，其次是歐洲 100,020 例，北美 67,784 例。因此，全球白血病的高發生率預計將推動血液惡性腫瘤市場的成長。同樣，根據全球癌症觀察站的數據，2020 年，北美地區報告了近 67,784 例白血病病例和估計 35,318 例多發性骨髓瘤病例。據白血病和淋巴瘤協會稱，2021 年，美國估計共有 397,501 人患有白血病或處於緩解期。因此，市場上血癌病例的顯著增加預計將在預測期內推動血液惡性腫瘤的市場價值。

越來越多的產品發布、合作夥伴關係和協作

許多公司正在實施各種策略性舉措，例如推出新產品、建立合作夥伴關係、促進合作以及進行併購，以增強其市場影響力。這反過來又對血液惡性腫瘤市場前景產生正面影響。例如，2020年10月，阿斯特捷利康印度製藥公司宣布推出Acalabrutinib 100 mg膠囊，用於治療各類白血病（白血病（CLL）和小淋巴細胞淋巴瘤），品牌為Calquence。同樣，2024年1月，塔塔紀念醫院開發出印度第一個治療白血病的口服化療藥物。這項突破性的發展有望徹底改變癌症治療，特別是像急性淋巴性白血病（ALL）這樣的血液惡性腫瘤，為傳統藥片提供更精確、更適合兒童的替代品。預計此類創新將在未來幾年增加血液惡性腫瘤市場的需求。

增加產品批准

各個相關監管機構擴大批准血液惡性腫瘤藥物，這為整體市場創造了積極的前景。例如，2020年9月，美國FDA核准百時美施貴寶的氮胞苷（Onureg）300毫克片劑CC-486繼續治療成人急性髓性白血病患者。同樣，2021 年 3 月，賽諾菲 SA 的 Sarclisa（isatuximab）聯合卡非佐米和地塞米松治療復發或難治性多發性骨髓瘤患者獲得美國 FDA 批准。與此一致，2021年2月，TG Therapeutics Inc.的UKONIQ（umbralisib）獲得美國FDA加速批准，這是一種口服、每日一次的磷酸肌醇3激酶（PI3K）δ和酪蛋白激酶1（ CK1）ε抑制劑，用於治療治療患有復發或難治性邊緣區淋巴瘤（MZL）的成人患者和患有復發或難治性濾泡性淋巴瘤（FL）的成人患者。批准用於治療血癌的藥物數量的顯著成長正在推動血液惡性腫瘤的市場價值。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球血液惡性腫瘤市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 白血病
    • 市場趨勢
    • 市場預測
  • 淋巴瘤
    • 市場趨勢
    • 市場預測
  • 多發骨髓瘤
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：透過治療

  • 化療
    • 市場趨勢
    • 市場預測
  • 放射治療
    • 市場趨勢
    • 市場預測
  • 免疫療法
    • 市場趨勢
    • 市場預測
  • 幹細胞移植
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場趨勢
    • 市場預測
  • 診斷中心
    • 市場趨勢
    • 市場預測
  • 研究中心
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112024A4133

The global hematologic malignancies market size reached US$ 60.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 122.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.

Hematologic Malignancies Market Analysis:

Major Market Drivers: The rising incidence of hematologic malignancies, coupled with an aging population, is driving demand for hematologic malignancy drugs. Additionally, the growing awareness about early diagnosis, along with improving diagnostic modalities, is also contributing to market growth.

Key Market Trends: Innovations in targeted therapies, immunotherapy, and personalized medicine, which are transforming treatment options, improving outcomes, and reducing side effects for patients with hematologic cancers, refer to one of the significant factors catalyzing the hematologic malignancies market revenue.

Competitive Landscape: Some of the leading companies operating in the global market include AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited, among many others.

Geographical Trends: The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.

Challenges and Opportunities: The hematologic malignancies market faces challenges such as high treatment costs, complex disease biology, and the need for personalized therapies. However, opportunities exist in advancing targeted therapies, immunotherapies, and diagnostic technologies to improve patient outcomes and meet the growing demand for effective and personalized cancer care solutions.

Hematologic Malignancies Market Trends:

Rising Prevalence of Blood Cancer

Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.

Growing Number of Product Launches, Partnerships, and Collaborations

Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.

Increasing Product Approvals

Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.

Global Hematologic Malignancies Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global hematologic malignancies market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, therapy, and end user.

Breakup by Type:

Leukemia

Lymphoma

Multiple Myeloma

Others

The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.

Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.

Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.

Breakup by Therapy:

Chemotherapy

Radiotherapy

Immunotherapy

Stem Cell Transplantation

Others

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiotherapy, immunotherapy, stem cell transplantation, and others.

As per the hematologic malignancies market overview by IMARC, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

Breakup by End User:

Hospitals

Diagnostics Centers

Research Centers

Others

The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.

Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.

Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.

Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast by IMARC indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the detailed profiles of the following key players:

AbbVie Inc.

AstraZeneca plc

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co. Inc

Novartis AG

Pfizer Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Hematologic Malignancies Market News:

June 2024: The University of Cincinnati Cancer Center launched a new treatment center dedicated specifically to blood cancers. It is the university's first state-of-the-art center devoted to blood cancer care in the United States.

June 2024: Fortis inaugurated a state-of-the-art facility for the specialized treatment of blood cancers and disorders.

January 2024: Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets.

Key Questions Answered in This Report:

  • How big is the hematologic malignancies market?
  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Leukemia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Stem Cell Transplantation
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck & Co. Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
  • Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2023
  • Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2023
  • Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
  • Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
  • Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Hematologic Malignancies Market: Competitive Structure
  • Table 7: Global: Hematologic Malignancies Market: Key Players